How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

806 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Full Text available with Trip Pro

Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. In Alzheimer's disease (AD), it is important to consider long-term effects, not only in patients receiving treatment, but also in subjects in whom therapy has been discontinued. The present analysis evaluates the long-term effects of galantamine on cognitive function in AD in terms of Mini-Mental State Examination (MMSE) scores for up to 7 years, using both clinical (...) data and epidemiological modeling. Consideration is given not only to patients continuing to receive galantamine therapy, but also to those who stop this treatment. In a retrospective review of medical notes, re-contacted study investigators obtained data from 258 patients originally recruited into three previously described randomized clinical trials involving galantamine: two placebo-controlled trials in mild-to-moderate AD (of 3 and 6 months' duration, followed by open-label extensions

2011 Journal of Alzheimer's disease : JAD Controlled trial quality: uncertain

102. Dementia: assessment, management and support for people living with dementia and their carers

dementia subtypes Managing medicines for all dementia subtypes 1.5.1 For guidance on managing medicines (including covert administration), see the NICE guidelines on managing medicines for adults receiving social care in the community and managing medicines in care homes. Pharmacological management of Alzheimer's disease Pharmacological management of Alzheimer's disease 1.5.2 The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended (...) as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.5.5 and 1.5.6. This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. 1.5.3 Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or or Dementia: assessment

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

104. Parkinson?s disease in adults

with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information. [6] At the time of publication (July 2017), cholinesterase inhibitors

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

106. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Full Text available with Trip Pro

Cholinergic medication for antipsychotic-induced tardive dyskinesia. Tardive dyskinesia (TD) remains a troublesome adverse effect of conventional antipsychotic (neuroleptic) medication. It has been proposed that TD could have a component of central cholinergic deficiency. Cholinergic drugs have been used to treat TD.To determine the effects of cholinergic drugs (arecoline, choline, deanol, lecithin, meclofenoxate, physostigmine, RS 86, tacrine, metoxytacrine, galantamine, ipidacrine, donepezil

2018 Cochrane

107. Donepezil

analysis). Secondary efficacy measures evaluated cognition, behavior, and function. The dual primary 2009 4. Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 11 May (...) 2016 Share Save Guidance on donepezil ( Aricept ), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects

2018 Trip Latest and Greatest

108. Topiramate

with a previous failure to topiramate treatment requiring prevention with Cefaly® according to the treating physician's suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous 2017 14. Adverse effects of galantamine, topiramate and cotrimoxazole Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole'', 1 July 2015 {1} {1} {1} | | > > > In the July (...) issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole FREE DOWNLOAD All in one sample page: from serious skin reactions with Alzheimer's drug

2018 Trip Latest and Greatest

109. Memantine

Guideline for Deprescribing Cholinesterase Inhibitors and Memantine . Sydney: The University of Sydney; 2018. The full guideline 2018 4. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 (...) Last updated: 11 May 2016 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new

2018 Trip Latest and Greatest

110. Drugs for Alzheimer's disease: finally delisted in France!

of copies of which have been downloaded from our website english.prescrire.org (1). In May 2018, France's Minister for Health took this negative harm-benefit balance into account. She decided that, from 1 August 2018, these drugs – donepezil, galantamine, rivastigmine and memantine – would be delisted, i.e. no longer reimbursed by the national health insurance system (2,3). This measure was not unexpected. In late 2016, the French Pharmacoeconomic (Transparency) Committee had concluded that these drugs

2018 Prescrire

111. Twenty-Five Pearls from 25 years (part 1)

provide harm data including serious adverse events that are not published elsewhere. 13 Donepezil has not been demonstrat- ed to improve outcomes of impor- tance to patients and caregivers (e.g. institutionalization or disability) Drugs for Alzheimer’s Disease [Apr-Aug 2005, issue 56]. Similarly, rivastigmine, galantamine and memantine have not been studied in terms of these important outcomes. It also concludes that acetylcholinesterase inhibitors cause gastrointestinal, muscular and other adverse

2019 Therapeutics Letter

117. Peri-operative care of people with dementia

and being in hospital. Key areas of supportconcern: 1 Knowingaboutthepersonwithdementia,forexample, making use of a ‘This is me’ or similar document (see ‘SourcesofFurtherInformation’); Table 2 Importantdruginteractionsbetweendementiamedicationanddrugsusedinanaesthesia. Half-life;hr Recommendation/effect Cholinesteraseinhibitors Galantamine 7 Discontinue a daybeforesurgery Rivastigmine 9 Discontinue a daybeforesurgery Donepezil 70 Notrecommended Memantine 60–100 Carewithketamine

2019 Association of Anaesthetists of GB and Ireland

120. Drugs to avoid

laxatives Moxifloxacin Bacterial infections Serious toxicity such as liver and cardiac disorders Ciprofloxacin, Ofloxacin Donepezil (Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Memantine Alzheimer’s and other dementias Minimal efficacy; disproportionate adverse effects such as severe vomiting and syncope Support from caregivers and family Alemtuzumab (Lemtrada), Natalizumab (Tysabri), Teriflunomide (Aubagio) Multiple sclerosis Disproportionate adverse effects such as infections and liver

2018 Therapeutics Letter

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>